Close

Peptide APS

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Celiac disease (CD) is a chronic inflammatory disease of the small intestine that affects ∼1.5% of whites. A small number of gliadin and glutenin peptides derived from gluten elicit this inflammatory CD4+ T cell response. CD is predominantly limited to genetically predisposed individuals, namely those who express HLA-DQ2 (DQA1∗0501-DQB1∗0201) and/or HLA-DQ8 (DQA1∗0301-DQB1∗0302). A third haplotype associated with CD is found in patients who are HLA-DQ2+ and HLA-DQ8+. These individuals can produce the trans dimer, HLA-DQ8.5 (DQA1∗0501-DQB1∗0302), which is formed by the HLA-DQ2.5 α chain and the HLA-DQ8 β chain, and has a unique peptide-binding repertoire.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0883 Human anti-Peptide APS T cell receptor (Bel502), pCDTCR1 Bel502 Human APSGEGSFQPSQENPQ HLA-DQA1*03:01/DQB1*03:02 Lentiviral vector   Add to Cart   Datasheet
TCR-YC0884 Human anti-Peptide APS T cell receptor (S13), pCDTCR1 S13 Human APSGEGSFQPSQENPQGS HLA-DQA1*03:01/DQB1*03:02 Lentiviral vector   Add to Cart   Datasheet
TCR-YC0885 Human anti-Peptide APS T cell receptor (T316), pCDTCR1 T316 Human APSGEGSFQPSQENPQGS HLA-DQA1*03:01/DQB1*03:02 Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.